Alpine Immune Sciences, Inc.’s Post

CDMOs are indispensable partners for #pharmaceutical companies, providing the essential flexibility and reliability in an era where resettling supply chains is increasingly vital. The global #CDMO market is projected to grow at approximately 7% annually through 2028, offering ripe opportunities for consolidation and expansion. 📈 Notably, Europe, home to 60% of CDMOs, presents a fertile ground for strategic partnerships and investments. 💡 Our latest publication delves into the opportunities within the CDMO landscape, highlighting avenues for substantial growth and strategic advantages: ➡️ https://lnkd.in/dvgMrvzm #RolandBerger

The WSJ article, using data from DealForma, discusses how major pharmaceutical companies have scaled down their acquisition strategies in 2024, focusing on smaller targets priced at $5 billion or less, primarily due to tighter regulatory scrutiny and a smaller pool of large-scale acquisition targets. Check out WSJ’s article. https://hubs.ly/Q02L2swt0

**CSPC Group Releases Latest Performance Report** On May 27, CSPC Group published its financial results for the first quarter of 2024. During the reporting period, the company achieved revenue of 8.983 billion RMB, marking an 11.5% year-over-year increase, and a net profit of 1.612 billion RMB, reflecting a 12.9% year-over-year growth. Today, Medilink Thera announced a licensing agreement with BioNTech for ADC technology. BioNTech will gain exclusive global options and corresponding licenses for several cutting-edge innovative target ADC products. BioNTech will pay a $25 million upfront fee, up to $1.8 billion in milestone payments, and a specified percentage of sales royalties. Additionally, CStone Pharma announced the grant of commercialization rights for Sugemalimab in 18 Central and Eastern European countries to Ewopharma. Under the terms of the licensing and commercialization agreement, CStone Pharmaceuticals will receive up to $51.3 million in upfront payments, as well as subsequent registration and sales milestone payments. #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical

ANI Pharmaceuticals is scheduled to report first quarter 2024 financial results on Friday, May 10th, before the market opens. Our President and CEO Nikhil Lalwani, and CFO Stephen Carey, will host a conference call to discuss the results at 8:30 am ET. For more information, including webcast access details, see our full press release (linked in comments below). #ANIP #pharmaceuticals #investors

The recent Congressional hearing put the spotlight on pharmaceutical CEOs from Johnson & Johnson, Merck, and Bristol Myers Squibb, focusing on the U.S.'s high prescription drug prices. This discussion is part of a broader debate ignited by the Inflation Reduction Act, which includes provisions for Medicare to negotiate drug prices directly, challenging the longstanding pricing autonomy of U.S. pharmaceutical companies. The industry argues this could affect access to new therapies and innovation, while proponents see it as a step towards controlling skyrocketing drug costs. Want to learn more? Link is in the comments.

Sponsorships can be a powerful tool for pharmaceutical companies to engage with communities and make a positive impact on health and wellness. Here are some examples of how pharmaceutical companies can use sponsorships to engage communities: https://lnkd.in/dBNPt8KM

ANI Pharmaceuticals is scheduled to report second quarter 2024 financial results on Tuesday, August 6th, before the market opens. Our President and CEO Nikhil Lalwani, and CFO Stephen Carey, will host a conference call to discuss the results at 8:30 am ET. For more information, including webcast access details, see our full press release (linked in comments below). #ANIP #pharmaceuticals #investors

In this piece, our team highlights the key take-aways from the European Commission’s report on enforcement in the pharmaceutical sector, and provides their reflections from a UK and US perspective

Novo Holdings announced a deal to acquire #Catalent, a leading global #CDMO. The deal is designed to help improve #supply challenges that have been holding back the growth of their blockbuster GLP-1 drug semaglutide, more well-known by brand names Ozempic and Wegovy. Read here to learn more as we unpack this #acquisition, discussing questions such as “what does it mean for customers?” and “does this deal reshape the CDMO market and #biopharma industry?” https://lnkd.in/gdsPJTxV

We worked with a $50 billion client in the pharmaceutical industry, where the head of EMEA needed to double the region’s revenue. How did we help him meet his targets? Find out in our case study below 👇 #marketprioritization #investmentstrategies #planning2025